An increase in project orders drives further site growth
- The first 100 aseptic batches at Vetter’s Rankweil site predict a successful future
- The site, established in 2021, is further expanding with state-of-the-art technology to provide reliable, high-quality clinical manufacturing services for customers
- A new uninterrupted power supply system will prevent any loss of power to the site as an added layer of safety for production
RAVENSBURG, Germany and RANKWEIL, Austria, September 05, 2024 / Biotech Newswire / -- Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has successfully completed the first 100 clinical batches of liquid and lyophilized vials at its dedicated site in Rankweil, Austria. Vetter Development Services Austria supports the manufacturing and quality control of medicinal products for clinical trials and displays an impressive development pace following its inception in 2021.
“Since opening our state-of-the-art clinical production site in Austria three years ago, we have witnessed a rapid rise in customer demand, to which we’ve responded by completing 100 clinical batches, with more on the horizon,” shared Dr. Claus Feussner, Senior Vice President of Vetter Development Service. “The facility is the European counterpart to our clinical manufacturing site near Chicago, Illinois, U.S., and we are proud to see both sites outperforming our expectations. It is a tribute, not only to the quality of the drug product candidates we manufacture with our customers, but the reliability we provide to them and their patients.”
In response to the current growth, Vetter is further investing in its Rankweil site. This includes a 14-by-24-meter roof extension, which will add a third floor to the building, creating more office space with individual workstations, cluster-style offices, and meeting rooms. An additional technical building will be built on the West side of the existing facility. This 3,400 square-meters, two-story building will house a technical workshop and a waste disposal center.
The basement of the building will feature an innovative uninterrupted power supply system which prevents harmful power disruptions for its operations. The new equipment makes the Rankweil site self-sufficient in power supply, which further increases production security. This supports Vetter’s commitment to best-in-class quality standards and improves the efficiency of the manufacturing processes. These construction plans are set to be finalized by mid-2025.
“It has been exciting few years for the Rankweil site,” said Dr. Martin Schwab, Vice President and Site Head Austria. “We look forward to witnessing this site continue to develop and grow. Our success is driven by a strong surge in project orders which will continue in the second half of the year. We are committed to further enhancing our clinical production efficiency in Rankweil, both through increased security initiatives, innovative technology, and a higher number of employees working at the site.”
© Vetter Pharma International GmbH: Rendering of the final building with its additional floor.
For high resolution please click the image.
Find the Vetter press kit and more background information here.
About Vetter
Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. As a global player, the independent pharmaceutical service provider is also present in the Asia-Pacific markets of Japan, China, South Korea and Singapore with sales locations. Around the world, small and large renowned pharma and biotech companies rely on the decades of experience, high quality, modern technologies, reliability, and commitment of its more than 6,600 employees. In close partnership with its customers, the Vetter team supplies patients all over the world with medicines, many of which are vital. The CDMO provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. With innovative solutions, Vetter develops prefilled drug-delivery systems together with its customers to continuously improve patient safety, comfort, and compliance. The company is an industry pioneer in sustainability and a socially and ethically responsible corporate citizen. The CDMO is a member of the UN Global Compact and Science Based Target initiative (SBTi) and received platinum status in the renowned EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost & Sullivan Customer Value Leadership Award and the recognition as Best Managed Company emphasize Vetter’s commitment to sustainable business. Founded in Ravensburg in 1950, the company remains family-owned to this day. For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.
Contact
Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg
Germany
+49 (0)751-3700-3729
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Manufacturing and Industrial Facilities; Drug Development; Clinical Trials as Topic; Pharmaceutical Services; Biotechnology; Pharmaceutical Preparations; Laboratories; Drug Packaging; Product Packaging; Drug Delivery Systems; Syringes; Outsourced Services; Commerce; Biological Products; Germany; Vetter; European clinical site; 100 aseptic batches; Rankweil, Austria; Contract Development and Manufacturing Organization (CDMO); Clinical manufacturing; Liquid and lyophilized vials; Expansion; Quality control; Clinical trials; Office space expansion; Technical building; Production security; Growth; Project orders; Innovative technology; Employees; Global presence; Sustainability; Patient safety; Drug delivery systems
Source: Biotech Newswire